152 related articles for article (PubMed ID: 32008329)
1. Biliary tract cancers: systemic therapy for advanced disease.
Martinez FJ; Shroff RT
Chin Clin Oncol; 2020 Feb; 9(1):5. PubMed ID: 32008329
[TBL] [Abstract][Full Text] [Related]
2. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
Cheon J; Lee CK; Sang YB; Choi HJ; Kim MH; Ji JH; Ko KH; Kwon CI; Kim DJ; Choi SH; Kim C; Kang B; Chon HJ
Ther Adv Med Oncol; 2021; 13():17588359211035983. PubMed ID: 34394748
[TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of biliary tract cancers.
Uson Junior PLS; Bogenberger J; Borad MJ
Curr Opin Gastroenterol; 2020 Mar; 36(2):85-89. PubMed ID: 31972599
[TBL] [Abstract][Full Text] [Related]
4. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
5. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
[TBL] [Abstract][Full Text] [Related]
6. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
Zhu AX; Hezel AF
Hepatology; 2011 Feb; 53(2):695-704. PubMed ID: 21274890
[TBL] [Abstract][Full Text] [Related]
7. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
8. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
[TBL] [Abstract][Full Text] [Related]
9. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Demir T; Moloney C; Mahalingam D
Crit Rev Oncol Hematol; 2024 Jul; 199():104388. PubMed ID: 38754771
[TBL] [Abstract][Full Text] [Related]
10. Continuum of care for advanced biliary tract cancers.
Vienot A; Neuzillet C
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):810-824. PubMed ID: 32586782
[TBL] [Abstract][Full Text] [Related]
11. Toward personalized treatment of advanced biliary tract cancers.
Geynisman DM; Catenacci DV
Discov Med; 2012 Jul; 14(74):41-57. PubMed ID: 22846202
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy for biliary cancers.
Jordan E; Abou-Alfa GK; Lowery MA
Chin Clin Oncol; 2016 Oct; 5(5):65. PubMed ID: 27829278
[TBL] [Abstract][Full Text] [Related]
13. A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.
Ramjeesingh R; Chaudhury P; Tam VC; Roberge D; Lim HJ; Knox JJ; Asselah J; Doucette S; Chhiber N; Goodwin R
Curr Oncol; 2023 Jul; 30(8):7132-7150. PubMed ID: 37622998
[TBL] [Abstract][Full Text] [Related]
14. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
Demols A; Bucalau AM; Mans L
Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
[TBL] [Abstract][Full Text] [Related]
15. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.
Tam VC; Ramjeesingh R; Burkes R; Yoshida EM; Doucette S; Lim HJ
Curr Oncol; 2022 Sep; 29(10):7072-7085. PubMed ID: 36290832
[TBL] [Abstract][Full Text] [Related]
16. Biliary tract carcinomas: from chemotherapy to targeted therapy.
Marino D; Leone F; Cavalloni G; Cagnazzo C; Aglietta M
Crit Rev Oncol Hematol; 2013 Feb; 85(2):136-48. PubMed ID: 22809696
[TBL] [Abstract][Full Text] [Related]
17. New Horizons for Precision Medicine in Biliary Tract Cancers.
Valle JW; Lamarca A; Goyal L; Barriuso J; Zhu AX
Cancer Discov; 2017 Sep; 7(9):943-962. PubMed ID: 28818953
[TBL] [Abstract][Full Text] [Related]
18. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapies in advanced biliary tract cancers.
Tella SH; Kommalapati A; Borad MJ; Mahipal A
Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers.
Boku N
Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]